Aclaris Therapeutics (NASDAQ:ACRS) Upgraded at StockNews.com

StockNews.com upgraded shares of Aclaris Therapeutics (NASDAQ:ACRS) from a sell rating to a hold rating in a research report report published on Friday morning.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Aclaris Therapeutics in a report on Tuesday, September 17th.

Aclaris Therapeutics Stock Performance

Aclaris Therapeutics stock opened at $2.05 on Friday. Aclaris Therapeutics has a 52 week low of $0.77 and a 52 week high of $2.72. The stock has a market capitalization of $146.43 million, a P/E ratio of -3.94 and a beta of 0.10. The stock has a fifty day moving average of $1.49 and a 200-day moving average of $1.30.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03). The company had revenue of $4.35 million for the quarter, compared to analyst estimates of $8.31 million. Aclaris Therapeutics had a negative return on equity of 40.26% and a negative net margin of 136.65%. On average, research analysts forecast that Aclaris Therapeutics will post -0.65 earnings per share for the current year.

Institutional Trading of Aclaris Therapeutics

Institutional investors have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Aclaris Therapeutics during the first quarter worth about $39,000. SG Americas Securities LLC lifted its holdings in Aclaris Therapeutics by 69.5% in the first quarter. SG Americas Securities LLC now owns 32,843 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 13,461 shares during the period. Russell Investments Group Ltd. boosted its position in Aclaris Therapeutics by 5,265.1% during the first quarter. Russell Investments Group Ltd. now owns 62,772 shares of the biotechnology company’s stock valued at $78,000 after acquiring an additional 61,602 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in Aclaris Therapeutics during the second quarter valued at $119,000. Finally, Assenagon Asset Management S.A. acquired a new stake in Aclaris Therapeutics during the 3rd quarter worth about $214,000. Institutional investors own 98.34% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.